Large-scale human study finds Ozempic (or similar medications) may reduce opioid overdose risk by 40%
A study published in the journal Addiction has found that people with opioid or alcohol use disorder (OUD, AUD) who take Ozempic or similar medications to treat diabetic/weight-related conditions appear to have a 40% lower rate of opioid overdose and a 50% lower rate of alcohol intoxication than people with OUD and AUD who do not take Ozempic or similar medications.
Ozempic (and similar medications) may be the new treatment for opioid and alcohol use disorder
A new study published in the scientific journal Addiction has found that people with opioid or alcohol use disorder (OUD, AUD) who take Ozempic or similar medications to treat diabetic/weight-related conditions appear to have a 40% lower rate of opioid overdose and a 50% lower rate of alcohol intoxication than people with OUD and AUD who do not take Ozempic or similar medications.
Weight loss drugs like Ozempic may help reduce overdose risks: Study
A study suggests that weight loss medications like Ozempic may help reduce the risk of overdose and alcohol intoxication in people with substance use disorders.
Ozempic: Weight Loss Drug May Help With Addiction Too
These medications have been associated with a 40 percent reduction in opioid overdose and 50 percent lower rate of alcohol intoxication.
Novo Nordisk's Weight Loss Drug Ozempic Associated With Reduced Opioid, Alcohol Use Disorder Incidences, Study Shows
A study found that prescriptions for GIP/GLP-1 RA drugs may reduce opioid overdose and alcohol intoxication rates in patients with OUD and AUD, offering potential new treatments for addiction.
Ozempic and similar drugs may lower risks for opioid and alcohol use disorders
A new study published in the scientific journal Addiction has found that people with opioid or alcohol use disorder (OUD, AUD) who take Ozempic or similar medications to treat diabetic/weight-related conditions appear to have a 40% lower rate of opioid overdose and a 50% lower rate of alcohol intoxication than people with OUD and AUD who do not take Ozempic or similar medications.
Could Ozempic and similar drugs be used to treat substance use disorders?
One of the most prominent medical developments in recent years has been the emergence of a class of drugs called glucagon-like peptide-1 receptor agonists (GLP-1 RAs). The best known of these drugs is Ozempic,
HealthDay on MSN33m
Weight-Loss Meds Like Wegovy Could Battle Alcoholism
Weight-loss and diabetes drugs like Ozempic, Wegovy, Mounjaro or Zepbound appear to help people battle alcoholism and opioid ...
Inverse5h
Ozempic Might Help Treat Two Common Addiction Disorders
A new study from Loyola University demonstrates that GLP-1 receptor agonists like Ozempic can help treat substance use ...
Ozempic could cut binge drinking and opioid abuse
Ozempic could cut binge drinking and opioid abuse, major research suggests. A US study of more than 800,000 people with a ...
HealthDay on MSN10h
Diabetes, High BMI, Previous Metformin Common in Teens With Rx for GLP-1 RAs
Patients aged 10 to 17 years who are prescribed glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are more likely to have ...
Medscape1d
GLP-1 Receptor Agonists Reduce Suicidal Behavior in Adolescents With Obesity
Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) given to adolescents with obesity was associated with a one-third ...
Diabetes, high BMI, previous metformin prescriptions are common in teens with prescriptions for GLP-1 RAs
Patients aged 10 to 17 years who are prescribed glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are more likely to have ...
clinicaladvisor.com1d
Risk for Suicidal Ideation, Attempts Down With GLP1-RA Treatment in Teens With Obesity
Researchers found that the study cohort had a significantly lower risk for suicidal ideation or attempts during 12 months of follow-up.
ahajournals.org6d
Muscle Mass and Glucagon-Like Peptide-1 Receptor Agonists: Adaptive or Maladaptive Response to Weight Loss?
Recent studies have shown that pharmacologic weight loss with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and ...